UK – Eliem Therapeutics, Inc., a Redmond, WA and Cambridge, England-based company delivering therapies that allow patients to live on their own terms, launched with $80m in financing since its inception in 2019.
Backers included RA Capital Management, Access Biotechnology, and Intermediate Capital Group (ICG). Led by President and Chief Executive Officer Bob Azelby, Eliem aims to develop and commercialize therapies treating neuronal excitability disorders such as chronic pain, depression, epilepsy, and anxiety – conditions that cause deep suffering for tens of millions of people each day.The company is progressing two clinical stage assets with clinically validated mechanisms of action for neurological diseases. They are: The company founders are:Company LeadersThe Board of Directors includes:02/04/2021
